E Fund Management Co. Ltd. Purchases Shares of 4,174 Biogen Inc. $BIIB

E Fund Management Co. Ltd. acquired a new position in shares of Biogen Inc. (NASDAQ:BIIB) in the second quarter, Holdings Channel.com reports. The institutional investor acquired 4,174 shares of the biotechnology company’s stock, valued at approximately $902,000.

A number of other large investors also recently modified their holdings of the stock. Reflection Asset Management purchased a new stake in shares of Biogen in the fourth quarter valued at about $25,000. WPG Advisers LLC boosted its position in Biogen by 417.9% in the fourth quarter. WPG Advisers LLC now owns 145 shares of the biotechnology company’s stock worth $26,000 after purchasing an additional 117 shares during the last quarter. Bell Investment Advisors Inc bought a new position in Biogen in the 2nd quarter valued at $27,000. First Horizon Corp purchased a new stake in shares of Biogen during the 4th quarter valued at $30,000. Finally, WFA of San Diego LLC bought a new stake in shares of Biogen during the 2nd quarter worth $32,000. Institutional investors own 87.93% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on BIIB shares. Wedbush raised their price objective on shares of Biogen from $201.00 to $215.00 and gave the stock a “neutral” rating in a report on Thursday, July 30th. Wall Street Zen cut shares of Biogen from a “buy” rating to a “hold” rating in a research note on Saturday, August 1st. Oppenheimer reissued an “outperform” rating and set a $300.00 target price on shares of Biogen in a research report on Wednesday, July 29th. The Goldman Sachs Group raised their price target on shares of Biogen from $231.00 to $238.00 and gave the stock a “buy” rating in a research note on Friday, April 24th. Finally, TD Cowen lifted their price target on shares of Biogen from $215.00 to $225.00 and gave the stock a “buy” rating in a report on Thursday, July 30th. One analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, thirteen have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $227.07.

Biogen Price Performance

BIIB stock opened at $221.56 on Thursday. The firm has a 50 day moving average of $204.91 and a 200-day moving average of $194.08. The company has a current ratio of 1.87, a quick ratio of 1.26 and a debt-to-equity ratio of 0.39. Biogen Inc. has a 12 month low of $131.52 and a 12 month high of $222.15. The firm has a market capitalization of $32.74 billion, a P/E ratio of 39.21, a price-to-earnings-growth ratio of 6.62 and a beta of 0.17.

Biogen (NASDAQ:BIIB) last posted its quarterly earnings data on Wednesday, July 29th. The biotechnology company reported $3.60 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.94 by $0.66. Biogen had a return on equity of 11.18% and a net margin of 8.32%.The company had revenue of $2.74 billion during the quarter, compared to analyst estimates of $2.46 billion. During the same quarter last year, the company earned $5.47 earnings per share. The firm’s quarterly revenue was up 3.4% on a year-over-year basis. Biogen has set its FY 2026 guidance at 12.000-13.000 EPS. As a group, sell-side analysts predict that Biogen Inc. will post 12.39 earnings per share for the current fiscal year.

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.